Novartis is acquiring biopharmaceutical company Tourmaline Bio for $1.4 billion to boost its cardiovascular pipeline.
Tourmaline develops pacibekitug, a drug used to treat atherosclerotic cardiovascular disease, according to a Sept. 9 news release from Novartis.
Novartis said the drug is in advanced phase 2 clinical trials and works to combat residual inflammatory risk more effectively than current therapies. The drug is being added to the drugmaker’s existing cardiovascular therapy portfolio, the release said.
